Bausch Health Companies (TSE:BHC) Raised to “Hold” at Raymond James Financial

Bausch Health Companies (TSE:BHC) was upgraded by stock analysts at Raymond James Financial to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

Separately, Barclays upgraded shares of Bausch Health Companies to a “hold” rating in a research report on Monday, December 8th. Two investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

Bausch Health Companies Stock Performance

TSE:BHC opened at C$9.56 on Monday. The stock has a 50 day simple moving average of C$9.08 and a 200 day simple moving average of C$9.04. The stock has a market cap of C$3.54 billion, a P/E ratio of 9.86, a PEG ratio of 0.21 and a beta of 0.69. Bausch Health Companies has a 1-year low of C$5.91 and a 1-year high of C$11.97. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of -1,831.94.

Bausch Health Companies (TSE:BHC) last posted its quarterly earnings data on Wednesday, October 29th. The company reported C$0.48 earnings per share for the quarter. Bausch Health Companies had a positive return on equity of 15.87% and a negative net margin of 1.88%.The firm had revenue of C$2.68 billion for the quarter. Research analysts anticipate that Bausch Health Companies will post 5.5472637 earnings per share for the current year.

About Bausch Health Companies

Bausch Health Companies Inc is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.